Increase in the pricing of lifesaving medicines affects the patient’s affordability
Though pharmaceutical companies always play a vital role in sustaining research and development of new drugs, the costs for lifesaving drugs have skyrocketed in recent years.
AbbVie contributing to Family Reach to support children battling Cancer
Cancer is one of the most expensive medical conditions to treat, where financial barriers affect a patient’s chance of survival. Up to 73% of adults and 1 out of every 3 families who have a child with cancer will experience cancer-related financial toxicity.
Abbvie partners with the Medicines Patent Pool to eliminate hepatitis C
Hepatitis C is a liver disease that can lead to cirrhosis, liver cancer, and death. The severity can range from a mild form lasting a few weeks to a serious illness that settles for life. An estimated 71 million people worldwide are carriers of the disease, 80% of whom are in low- and middle-income countries, and 400,000 die each year. Access to hepatitis C virus (HCV) diagnosis and treatment is improving, but it is still too expensive and by 2017 only 20% of patients had been diagnosed and only 7% had received treatment.
Abbvie’s Waste Management Efficiency towards EnvironmentWaste collection is important for the protection of environment and healthy population. Recycling waste conserves the natural resources and reduces cost of products. The Pharma giant company Abbvie, focused on driving consistent and sustainable improvements in reducing its environmental footprint. Abbvie is working on the target of reducing its CO2 emissions and water usage by atleast 50 percent by 2035. It is also planning to implement zero waste to landfill at all AbbVie sites around the world by 2035. In 2017, AbbVie reduced absolute total waste by 7 percent; maintained the recycling rate of 37 percent and reduced absolute water consumption by 8 percent. These activities made AbbVie to receive the gold-class distinction from sustainable investment specialist RobecoSAM in both 2017 and 2018 for excellent performance in social, economic and environmental practices. In its Ireland operations alone, AbbVie has invested about €6 million in sustainable and renewable energy programmes since 2013. Campoverde in Ireland has the highest recycling rate of any of the AbbVie manufacturing sites globally, and the team’s success over the years has been recognized by the EU Eco-Management and Audit Scheme (EMAS), which recognized AbbVie for its continuous improvement for environmental performance. Through the company’s initiatives and policies, AbbVie works hard to increase the efficiency of waste management.
Abbvie’s Engagement in Preventing Neglected Tropical DiseasesNeglected tropical diseases (NTDs) are a diverse group of tropical infections which are common in low-income populations in developing regions of Africa and Asia. They are caused by a variety of pathogens such as viruses, bacteria, protozoa, and helminths. According to the World Health Organization, the disease affects more than one billion people around the world. The efforts to prevent and cure the disease require innovation in drug delivery and development. Abbvie, a biopharma company has made around 400 well-professionalized scientists to dedicate nearly 40,000 pro-bono hours on drug development projects to solve NTDs. Abbvie supports a collaborative disease eradication programme named London Declaration on Neglected Tropical Diseases to control, eliminate and prevent 10 neglected tropical diseases by 2020. Since 2011, AbbVie’s scientists have increased the number of volunteer hours contributed to the product development partnerships with DNDi (Drugs for Neglected Diseases initiative - non-profit drug research organization), they are engaged with from about 5,000 a year to more than 17,000 hours a year. The allocation of these hours brings development in activities such as discovery, development sciences and drug product development. For e.g. In March 2015, the AbbVie along with DNDi and other partners started researching on Filarial diseases to develop ABBV-4083 as an anti-Wolbachia therapy and assess its macrofilaricidal efficacy. In 2018,The Phase I study, which took place at AbbVie’s Clinical Pharmacology Research Unit, was completed and the results support progression to Phase II. As the Neglected Tropical Diseases widely affects the poor people around the world, Abbvie makes efforts to improve health outcomes through supporting various Non Profit Organizations to control and eliminate NTDs around the world.